The discovery of colony-stimulating factor 3 receptor (CSF3R) mutations in the majority of CNL patients14 revolutionized our understanding of the pathogenesis of this disease, provided a biomarker for CNL diagnosis, and paved the way for therapeutic targeting with small-molecule tyrosine kinase inhibitors (TKI). This evidence concerns the gene CSF3R and chronic neutrophilic leukemia.